key: cord-0746314-zrrv2841
authors: Murhekar, Manoj V.; Bhatnagar, Tarun; Thangaraj, Jeromie Wesley Vivian; Saravanakumar, V.; Kumar, Muthusamy Santhosh; Selvaraju, Sriram; Rade, Kiran; Girish Kumar, C. P.; Sabarinathan, R.; Turuk, Alka; Asthana, Smita; Balachandar, Rakesh; Bangar, Sampada Dipak; Bansal, Avi Kumar; Chopra, Vishal; Das, Dasarathi; Deb, Alok Kumar; Devi, Kangjam Rekha; Dhikav, Vikas; Dwivedi, Gaurav Raj; Muhammad Salim Khan, S.; Sunil Kumar, M.; Laxmaiah, Avula; Madhukar, Major; Mahapatra, Amarendra; Rangaraju, Chethana; Turuk, Jyotirmayee; Yadav, Rajiv; Andhalkar, Rushikesh; Arunraj, K.; Bharadwaj, Dinesh Kumar; Bharti, Pravin; Bhattacharya, Debdutta; Bhat, Jyothi; Chahal, Ashrafjit S.; Chakraborty, Debjit; Chaudhury, Anshuman; Deval, Hirawati; Dhatrak, Sarang; Dayal, Rakesh; Elantamilan, D.; Giridharan, Prathiksha; Haq, Inaamul; Hudda, Ramesh Kumar; Jagjeevan, Babu; Kalliath, Arshad; Kanungo, Srikanta; Krishnan, Nivethitha N.; Kshatri, Jaya Singh; Kumar, Alok; Kumar, Niraj; Vinoth Kumar, V. G.; Naga Lakshmi, G.G.J.; Mehta, Ganesh; Mishra, Nandan Kumar; Mitra, Anindya; Nagbhushanam, K.; Nimmathota, Arlappa; Nirmala, A. R.; Pandey, Ashok Kumar; Prasad, Ganta Venkata; Qurieshi, Mariya Amin; Reddy, Sirasanambatti Devarajulu; Robinson, Aby; Sahay, Seema; Saxena, Rochak; Sekar, Krithikaa; Shukla, Vijay Kumar; Singh, Hari Bhan; Singh, Prashant Kumar; Singh, Pushpendra; Singh, Rajeev; Srinivasan, Nivetha; Varma, Dantuluri Sheethal; Viramgami, Ankit; Wilson, Vimith Cheruvathoor; Yadav, Surabhi; Yadav, Suresh; Zaman, Kamran; Chakrabarti, Amit; Das, Aparup; Dhaliwal, RS; Dutta, Shanta; Kant, Rajni; Khan, A M; Narain, Kanwar; Narasimhaiah, Somashekar; Padmapriyadarshini, Chandrasekaran; Pandey, Krishna; Pati, Sanghamitra; Patil, Shripad; Rajkumar, Hemalatha; Ramarao, Tekumalla; Sharma, YK; Singh, Shalini; Panda, Samiran; Reddy, D.C.S.; Bhargava, Balram
title: SARS-CoV-2 sero-prevalence among general population and healthcare workers in India, December 2020 - January 2021
date: 2021-05-19
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.05.040
sha: 30241b0856947423eb17df345f4cde5f2762d2d7
doc_id: 746314
cord_uid: zrrv2841

Background Earlier serosurveys in India revealed SARS-CoV-2 seroprevalence of 0.73% during May-June and 7.1% during August-September 2020. We conducted the third serosurvey during Dec 2020 and Jan 2021, to estimate the seroprevalence of SARS-CoV-2 infection among general population and healthcare workers (HCWs) in India. Methods We conducted the serosurvey in the same 70 districts selected for the first and second serosurveys. From each district, we enrolled at least 400 individuals aged ≥ 10 years from general population and 100 HCWs from sub-district level health facilities. Sera from general population were tested for presence of IgG antibodies against nucleocapsid (N) and spike protein (S1-RBD) of SARS-CoV-2, whereas sera from HCWs were tested for anti-S1-RBD. We estimated weighted seroprevalence adjusted for assay characteristics. Results Of the 28,598 sera from general population, 4585 (16%) had IgG antibodies against N, 6647 (23.2%) against S1-RBD and 7436 (26%) against either. The weighted and assay characteristic adjusted seroprevalence against either of the antibodies was 24.1 (95%CI: 23.0%-25.3%). Among 7385 HCWs, the seroprevalence of anti-S1-RBD IgG antibodies was 25.6% (95% CI: 23.5%-27.8%). Conclusions Nearly one in four individuals aged > = 10 years from general population as well as HCWs in India were exposed to SARS-CoV-2 by December 2020.

Population based serosurveys are recommended to estimate the proportion of population already infected with SARS-CoV-2. Repeated cross sectional serosurveys conducted in the same geographical location provide estimates to monitor trends over a period of time (World Health Organization, 2020a) . The information from the repeated cross-sectional surveys are valuable for the public health decision makers to design and revise containment strategies. The meta-analysis estimated an overall global seroprevalence of 8.0% in the general population and among healthcare workers was 17.1% (Chen et al., 2021) .

With more than 10 million laboratory confirmed cases and nearly 150,000 reported deaths as of 31 December 2020, India has the second largest number of COVID-19 cases reported globally (World Health Organization, 2020b) . The nationwide lockdown imposed during March to May 2020 in India was relaxed in a phased manner since June 2020, allowing inter-state and inter-district movement of people as well as restoration of economic activities (Ministry of Home Affairs, Government of India, 2021 India, , 2020 . The two population-based serial serosurveys conducted in 70 Indian districts indicated that the prevalence of SARS-CoV-2 infection among adults had increased ten-fold, from 0.73% (95% CI: 0.34-1.13) in May-June, 2020 to 7.1% (95% CI: 6.2-8.2) in August-September, 2020 (Murhekar et al., 2020 (Murhekar et al., , 2021 . The number of infections per reported COVID-19 case decreased from 81.6-130.1 in May-June to 26-32 in August-September, mainly on account of improvement in testing capacity and number of tests done in the country (Murhekar et al., 2020 (Murhekar et al., , 2021 .

SARS-CoV-2 poses a high occupational risk to healthcare workers (HCWs), who are at the forefront of management of COVID-19 cases in hospital settings. Knowledge of the burden of infection among healthcare workers is important to gauge the risk of within and outside hospital transmission of SARS-CoV-2, and evaluate the in-hospital infection control practices and adherence to non-pharmaceutical interventions as well (Piccoli et al., 2021) .

The number of COVID-19 cases in India has shown a downward trend since mid-September, with the reported number of cases declining from more than 90,000 per day in September to less than 20,000 cases per day in December 2020. This declining trend was seen in all Indian states, except in the states of Kerala (FETP Network-India, 2021).

We conducted the third round of nationwide serosurvey in December 2020-January J o u r n a l P r e -p r o o f 2021 to estimate the seroprevalence of SARS-CoV-2 antibodies in the general population and determine the trends in infections since the previous serosurveys. We also estimated the seroprevalence among HCWs working in sub-district level public health facilities.

We followed the same survey methodology as in the first and second nationwide serosurveys (Murhekar et al., 2020 (Murhekar et al., , 2021 (online supplementary material). Briefly, the third population-based serosurvey was conducted in the same 700 clusters (villages in rural areas and wards in urban areas) from randomly selected 70 districts across India, where previous serosurveys were done. We aimed to select a minimum of 400 individuals aged 10 years and above from each district with a total sample size of 28,000 individuals (online supplementary material). The survey teams first selected four random locations from each cluster. Starting from a random household in each location, contiguous households were visited till a minimum of four households were enrolled. All household members aged 10 years and above who were permanent resident of the area were enumerated and consenting individuals present at the time of visit of survey team were included in the survey. No additional visits were made to include households which were locked or household members not present at the first visit. In order to select at least 40 individuals from each cluster, the field teams visited a minimum of 4 households from each of the 4 random points and enrolled at least 10 individuals per random starting locations. In case the teams did not get 10 eligible individuals from the J o u r n a l P r e -p r o o f four households, more households were visited. The survey was conducted between December 18, 2020 and January 6, 2021.

From each of the 70 districts identified for the general population survey, we selected 2-3 sub-district level public health facilities (e.g. taluk or sub-divisional hospital, community or primary health center) closest to the selected cluster/s for household survey. All consenting individuals working in these facilities were included to ensure participation of a minimum of 100 HCW from each district.

Eligible individuals from the general population and HCWs who consented to participate were interviewed using the Open Data Kit mobile application (https://opendatakit.org/)

to collect information about socio-demographic details, history of symptoms suggestive of COVID-19 since March, 2020 (eg, fever, cough, shortness of breath, sore throat, new loss of taste or smell, fatigue), contact with laboratory confirmed COVID-19 cases, and history of COVID-19 illness. 3-5 mL of venous blood was collected from each participant, and centrifuged sera were transported to ICMR-National Institute of Epidemiology, Chennai under cold chain.

Serum samples collected from individuals from general population were tested for the presence of IgG antibodies against SARS-CoV-2 on the Advia Centaur Immunoassay J o u r n a l P r e -p r o o f system using the Siemens SARS-CoV-2 IgG Assay (Siemens Healthineers India, Mumbai) and Abbott Architect i2000SR automated analyzer using the Abbott SARS-CoV-2 IgG assay (Abbott Park, IL, USA). The Siemens assay detects IgG antibodies against S1

protein of the receptor binding domain (S1-RBD) whereas the Abbott assay detects IgG antibodies against nucleocapsid (N) protein of SARS-CoV-2. Sera from HCWs were tested only for IgG antibodies against S1-RBD. The sensitivity and specificity of the Siemens IgG assay is 100% and 99.90% respectively, while the Abbott IgG assay has a sensitivity of 100% and specificity of 99.6% (Center for Devices and Radiological Health, 2021). Sera with cut-off indices (COI) of >=1.0 on Siemens IgG assay or >=1· 4 on Abbott IgG assay were considered as positive for IgG antibodies against SARS-CoV-2. As a part of quality control, 150 positive and 150 negative sera for each of these assays were re-tested.

We described the characteristics of study participants as percentages, means, and standard deviations (SDs). The reported occupations were categorized as high-risk and low-risk categories, on the basis of the potential risk of exposure to a known or unknown COVID-19 case. For ex: occupations such as health care workers, police or security personnel, shopkeepers, bus or taxi drivers or bank employees were considered as highrisk occupations and farmers, retired employees, students or information technology professionals, homemakers were considered as low-risk occupations (Murhekar et al., 2021) . We separately estimated the weighted seroprevalence of IgG antibodies against N protein and S1-RBD, along with 95% confidence interval (CI), using a random-effects model to account for cluster sampling. We calculated sampling weights as a product of J o u r n a l P r e -p r o o f the inverse of the sampling fraction for the selection of districts and the selection of villages or wards from each district. The weighted seroprevalence was further adjusted for the sensitivity and specificity of the respective assays (Sempos and Tian, 2021) . We estimated the overall seroprevalence in the general population by considering serum samples positive to any of the assays. The weighted overall seroprevalence was adjusted for the joint sensitivity and specificity of two assays (Sempos and Tian, 2021) .

Seroprevalence among HCWs was considered on the basis of anti-S1 assay only. We also calculated the overall seroprevalence by age group, sex, area of residence, and COVID-19-related characteristics of study participants.

The first serosurvey was conducted only among adults, whereas individuals aged >=10 years were surveyed in the second and third surveys. The serum samples in the second round were tested only for IgG antibodies against N protein using Abbott assay. For comparing the seroprevalence in the three surveys, we randomly selected one adult per household from the survey database, and estimated the adjusted seroprevalence of IgG antibodies against N protein among these adults.

We applied the overall adjusted seroprevalence in the general population aged 10 years or older to the total population of the entire country aged >=10 years to estimate the total number of SARS-CoV-2 infections. Studies indicate that IgG antibodies start appearing between 7 and 14 days after onset of symptom and RT-PCR positivity (Long et al., 2020) . We estimated the infection to case ratio by dividing the estimated number of SARS-CoV-2 infections by the number of reported COVID-19 cases detected by RT-PCR or rapid antigen test, at 1 week (Dec 19, 2020) and 2 weeks (Dec 12, 2020) before the median survey date (Dec 26, 2020).

IgG antibodies against SARS-CoV-2 infection decline over time (Ripperger et al., 2020; Bolotin et al., 2021) . The cut-off indices (COI) for different assays specified by manufacturers are based on ≥ 14 days convalescent sera. Lowering the COIs could improve the sensitivity of the assays used for population based serosurveys (Bolotin et al., 2021) . We calculated the seroprevalence using lower COI of >0.54 for Abbott and 0.32 for Siemens IgG assays as suggested by Irsara et al (Irsara et al., 2021) . We also estimated the seroprevalence using the lowest value of sensitivity (90.8% for Abbott assay and 78.8% for Siemens assay and specificity (99.3% for Abbott assay and 100%

Siemens assay) estimated through external validation studies. (See online supplementary material).

We obtained written informed consent from individuals aged 18 years or older and assent from children aged between 12 and 17 years, with written informed consent from their parents or guardians, before the survey (Indian Council of Medical Research, 2017).

The Institutional Human Ethics Committee of ICMR-National Institute of Epidemiology, Chennai approved the study protocol.

Seroprevalence among general population (Table 1) .

Of the 28,598 individuals tested, 4585 (16%) had IgG antibodies against N protein and 6647 (23.2%) had IgG antibodies against S1-RBD. The weighted and assay characteristics adjusted seroprevalence of IgG antibodies against N and S1-RBD protein was 14.3% (95% CI: 13.6% -15.0%) and 21.5% (95% CI: 20.4% -22.6%), respectively.

Overall, 7436 individuals had IgG antibodies against either N or S1-RBD protein, with the weighted and assay characteristic adjusted seroprevalence of 24.1% (95% CI: 23.0% -25.3%) ( 

In order to be able to compare the seroprevalence among adults between the three serosurveys, we randomly selected 16,565 adults, one per household, from the database. Of these, 2657 had IgG antibodies against N-protein with weighted and adjusted seroprevalence of 14.3% (95% CI: 13.5%-15.1%). The weighted seroprevalence of IgG antibodies against either N or S-RBD protein was 24.3% (95% CI: 23.1% -25.6%).

Applying the overall seroprevalence to the population aged 10 years and above, we estimated that 27, 14, 04, 207 (95% CI: 25, 90, 16, 49, 18, 110) 

The third serosurvey findings indicated that nearly 24% of India's population aged ten years and above was exposed to SARS-CoV-2 infection by December 2020, with an estimated 271 million infections. The seroprevalence did not differ by sex but was lower among adults aged 18-44 years and in rural areas although lower than the urban areas.

The results also indicate that about one-fourth of healthcare workers working in the peripheral public sector health facilities were positive for IgG antibodies.

We used antibody assays to detect IgG against N and S1-RBD proteins of SARS-CoV-2 in this survey. N-protein assays are reported to be more sensitive than S1 assays in detecting antibodies in mildly infected patients that are reported to show absent or delayed, and lower SARS-CoV-2 antibody responses (Özçürümez et al., 2020; van Tol et al., 2020) . It has been shown that the anti-nucleocapsid antibodies appear earlier than the spike antibodies and therefore, may increase the clinical sensitivity of the assay, if samples are drawn early (Rikhtegaran Tehrani et al., 2020) . In our survey, 800 individuals were reactive for N-protein but negative for S1-RBD, possibly suggesting early infections, IgG antibody response against different viral antigens is heterogeneous in nature and does not always correlate with each other (McAndrews et al., 2020) . Therefore, detecting antibodies against two different antigens, with high sensitivity and specificity, is needed to confirm the findings and avoid false-negative results in surveillance studies (Irsara et al., 2021) .

The seroprevalence studies provide information about the extent of transmission in the past and help to understand the future course of the pandemic (World Health Organization, 2020a; Chen et al., 2021) . The seroprevalence of IgG antibodies against SARS-CoV-2 among individuals aged >=10 years in India, has increased from 6.6% in August to 24.1% in December 2020. The prevalence of IgG antibodies against N protein between the two serosurveys has increased at least by 2.2 folds. Serum samples from the previous serosurvey were not tested for anti-S1-RBD IgG antibodies. During the same period, the reported number of COVID-19 cases in India has increased 3.5 folds. The seroprevalence was significantly lower in the 18-44 years age group in contrast to the second serosurvey when the prevalence was similar across age groups. Between August and December 2020, the age specific seroprevalence of anti-N antibodies among individuals aged 18-44 years has increased by 1.8 folds, and by 2.6-3.1 folds in the remaining age groups (See online supplementary material).

The lower seroprevalence in the active and productive age group compared with other age groups is not consistent with the transmission pattern of COVID-19. This age group was exposed to infection early in the pandemic as reflected in the relatively high incidence of COVID-19 among this age group during January-April 2020 (ICMR COVID J o u r n a l P r e -p r o o f Study Group , 2020). The lower seroprevalence in this age group therefore could be due to relatively higher waning of IgG antibodies compared to other age groups. It is noteworthy to mention here that during the second survey, 81% of individuals with RT-PCR confirmed infection were seropositive as against 63% during the third serosurvey.

We found higher sero-prevalence of SARS-CoV-2 infection in urban areas compared to the rural areas. Although this pattern was similar to the serosurvey in August 2020, the seroprevalence was not different in slum and non-slum urban areas as observed during August 2020. Between August and December 2020, the increase in seroprevalence was highest in rural areas (2.5 fold), followed by urban non-slum (1.93 fold) and urban slum (1.07 fold) reflecting the varied distribution of susceptible population in these areas. The declining trend in the reported number of COVID-19 cases in India since mid-September 2020 points towards a reduction in transmission that could be attributed to higher seroprevalence in urban slum and non-slum areas considering these locations to be the drivers of the epidemic in the country (Malani et al., 2021b) . Our serosurvey findings also indicate that a large proportion of individuals in the rural area continue to remain susceptible to infection. Similar finding was observed in the recent serosurvey conducted in the India states of Karnataka and Tamil Nadu (Mohanan et al., 2021; Malani et al., 2021a) . The seroprevalence among HCWs (25.6%) observed in our study was much higher than the 8.7% prevalence estimated in a systematic review and meta-analysis among HCWs (Galanis et al., 2021) . A comparable seroprevalence among clinical, paramedical, field and administrative workers in health facilities and by place of contact with known COVID- (Murhekar et al., 2020) . In the second serosurvey, a laboratory assay which detected IgG antibodies against nucleocapsid protein of the virus was used (Murhekar et al., 2021) .

As antibodies against nucleocapsid protein of SARS-CoV-2 virus have been shown to decline faster over a period of time, the actual seroprevalence might have been underestimated and thereby the actual number of infections (Ripperger et al., 2020; Bolotin et al., 2021) . In order to overcome these limitations, the serum samples were tested with both anti-nucleocapsid and anti-S1 assays in the third survey. Third, we estimated the infection to case ratio based on the reported number of COVID-19 cases. The completeness of reporting of COVID-19 cases could be variable in different Indian states.

In conclusion, the findings of the third nationwide serosurvey indicate that nearly one in four individuals aged 10 years or older from general population as well as healthcare workers were exposed to SARS-CoV-2 in India by December 2020. The seroprevalence increased between August and December 2020, and the decline in the number of COVID-19 cases seen in India since mid-September could be on account of higher seroprevalence in urban areas. As three fourth of the population is still susceptible, it is necessary to continue ongoing surveillance for COVID-19 cases, especially in rural areas.

It is also necessary to continue implementation of non-pharmaceutical interventions such as physical distancing, use of face masks and hand-hygiene. Govt of India has initiated COVID-19 vaccination since January 2021, targeting healthcare and frontline workers in the first phase and individuals aged above 50 years in the second phase (Ministry of Health and Family Welfare, Government of India, 2020). As higher proportion of rural population is susceptible to infection and considering limited healthcare facilities in rural areas especially oxygen beds (Kumar et al., 2020) , elderly population in the rural areas may be prioritized for COVID-19 vaccination. 

Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline

Office of the Registrar General & Census Commissioner

Center for Devices and Radiological Health

Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis

COVID-19 Resource Center

Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and metaanalysis

Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19

Indian Council of Medical Research. National ethical guidelines for biomedical and health research involving human participants

Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay

COVID-19: Challenges and its consequences for rural health care in India

Antibody responses to SARS-CoV-2 in patients with COVID-19

Seroprevalence in Tamil Nadu in October

Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India

Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity

Ministry of Health and Family Welfare, Government of India. COVID-19 Vaccines: Operational guidelines

Ministry of Home Affairs, Government of India. Government of India issues Orders prescribing lockdown for containment of COVID-19 Epidemic in the country 2021. pib.gov.in/Pressreleaseshare.aspx?

Ministry of Home Affairs, Government of India. Guidelines for Phased Re-opening (Unlock

As per the Ministry of Home Affairs Order No. 40-3/2020-DM-I (A) dated 30th

Prevalence of SARS-CoV-2 in Karnataka, India

Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey

findings from the second nationwide household serosurvey

SARS-CoV-2 antibody testing-questions to be asked

Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. The Lancet Regional Health

Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity

Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error

Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach

110) Number of reported COVID-19 cases

Infection Case ratio

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.J o u r n a l P r e -p r o o f

 Table 2 : Sero-prevalence (%) of IgG antibodies against SARS-CoV-2 infection, India, Aug-Sept 2020 General population aged 10 years and above Health Care Workers

Anti-S1-RBD antibodies Anti-N or ant-S antibodies Anti-S1-RBD antibodies